Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

BACKGROUND: In a phase 1 dose-escalation study, combined inhibition of T-cell checkpoint pathways by nivolumab and ipilimumab demonstrated a high objective response rate, including complete responses in patients with advanced melanoma. METHODS: In this double-blind study, 142 treatment-naïve patient...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:N Engl J Med
Prif Awduron: Postow, Michael A., Chesney, Jason, Pavlick, Anna C., Robert, Caroline, Grossmann, Kenneth, McDermott, David, Linette, Gerald P., Meyer, Nicolas, Giguere, Jeffrey K., Agarwala, Sanjiv S., Shaheen, Montaser, Ernstoff, Marc S., Minor, David, Salama, April K., Taylor, Matthew, Ott, Patrick A., Rollin, Linda M., Horak, Christine, Gagnier, Paul, Wolchok, Jedd D., Hodi, F. Stephen
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2015
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5744258/
https://ncbi.nlm.nih.gov/pubmed/25891304
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1414428
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg